Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Alliance for Clinical Trials in Oncology
Active, not recruiting ID
For more information, see NCT03087708
This randomized pilot clinical trial studies the side effects and best dose of naloxegol and
to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer.
Naloxegol may relieve some of the side effects of opioid pain medication and fight off future
growth in the cancer.
Naloxegol, Placebo, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Pankaj Gupta, MD

See list of participating sites